Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Background: this study aims to evaluate the efficacy of tixagevimab/cilgavimab (Evusheld™) against various SARS-CoV-2 variants, including newer Omicron sublineages, in an immunocompromised cohort and in vitro. Study design: Conducted in Italy, this research involves immunocompromised patients who re...

Full description

Bibliographic Details
Main Authors: Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Elisabetta Svizzeretto, Andrea Tommasi, Carlo Pallotto, Elisabetta Schiaroli, Daniela Francisci
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Viruses
Subjects:
COVID-19
SARS-CoV-2
tixagevimab
cilgavimab
variant
immunocompromised
Online Access:https://www.mdpi.com/1999-4915/16/3/354

Internet

https://www.mdpi.com/1999-4915/16/3/354

Similar Items